NKp46

NKp46

NKp46 詳細

Molecule Name
Natural cytotoxicity triggering receptor 1
分子の別称
NCR1,LY94,CD335,NK-p46,hNKp46
Drug Development Progress
治験薬の数3
市販薬剤の数0
研究&開発段階Phase 2 Clinical
ターゲットの別称
NK cell-activating receptor,NK-p46,Lymphocyte antigen 94 homolog,NKp46,hNKp46,Lymphocyte Antigen 94 Homolog (Activating NK-Receptor; NK-P46),Natural killer cell p46-related protein,LY94,Lymphocyte Antigen 94 (Mouse) Homolog (Activating NK-Receptor; NK-P46),CD335 Antigen,CD335
バックグランド
Natural cytotoxicity triggering receptor 1 (NCR1) is also known as Natural killer cell p46-related protein (NK-p46), Lymphocyte antigen 94 homolog (LY94), CD antigen CD335, which belongs to the natural cytotoxicity receptor (NCR) family. NCR1 contains two Ig-like (immunoglobulin-like) domains. NCR1 interacts with CD247 and FCER1G. NCR1 / CD335 may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis.

NKp46 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
NY-303NY-303Phase 2 ClinicalNAYA Biosciences Inc
Carcinoma, Hepatocellular; Solid tumours
詳細
IPH-6501IPH-6501; IPH-65Phase 2 ClinicalInnate Pharma SA
Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms
詳細
SAR-443579SAR-443579; SAR443579; SAR'579; IPH6101; IPH-6101Phase 1 ClinicalSanofi
Blastic Plasmacytoid Dendritic Cell Neoplasm; Hematologic Diseases; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
詳細